Alia Therapeutics

We extend our warmest wishes for a happy holiday season and a prosperous New Year. May this time be filled with joy, health and success for you and your loved ones. Happy Holidays and Happy New Year! Alia’s team #aliaens #happyholidays #aliatx #crispr #genetherapy

Alia Therapeutics is present at ESGCT Rome, the 31st Annual Meeting of the European Society of Gene & Cell Therapy. Meet Matteo Bello, PhD candidate at Alia Therapeutics and at Università di Trento, presenting poster on “A mutation-independent approach to treat autosomal dominant retinitis pigmentosa exploiting compact CRISPR effectors from the human microbiome”. Poster session III - Gene editing: Thursday October 24th between 14-15.30, Poster 619 Alia Therapeutics has a vision to revolutionize medicine by curing genetic diseases at their roots. Our thesis: The diversity and complexity of human genetic diseases demands a customized approach and relying on a limited set of enzymes wouldn’t suffice. Alia’s versatile portfolio of novel CRISPR systems expands the range of targetable genomics sites and increases the precision of genetic modifications, bringing gene editing to the next level of specificity and safety, which is required for therapeutic applications. Learn more at https://lnkd.in/dhVhCzw4 #ESGCT #rome #genetherapy #geneediting #CRISPR #retinitispigmentosa

The European Biotech Week is here: from 24 September to 1 October, a series of events will celebrate at European level the key role of biotechnology in the quality of life of all of us. Alia Therapeutics in collaboration with Trentino Sviluppo S.p.A. will be present: 🔴 We have been featured in the short documentary: "Trentino, presente e futuro delle Life Science", released online on September 24th 🔴 Our labs, hosted within the newly established Life Sciences Hub in Pergine Valsugana, will be open for guided tours on October 1st More information here: https://lnkd.in/dUvNsHxJ

We are excited to announce an opening for a Finance Manager at Alia Therapeutics, based in Trento. If you are passionate about finance and eager to contribute to a dynamic and innovative team, we would love to hear from you! #joboffer #jobopening #hiring #Trento

A message from our CEO, Letizia Goretti:

We regret to inform you that Alia Therapeutics has been the victim of a scam: it has come to our attention that alleged headhunters are recruiting for roles under the name of Alia via online social media platforms. Alia Therapeutics and our colleagues have not authorized any of such recruitment activities and we intend to prosecute those who are using our name illegally.

Today we reached an important milestone at Alia Therapeutics: the opening of our brand new headquarter and laboratory space fully equipped with state-of-the-art technology to accelerate our mission inside the new life science hub from Trentino Sviluppo S.p.A., located in Pergine, in the stunning surroundings of the Dolomites. It was a day of celebration and reflection on the importance of academic excellence, talent, infrastructure, and private investment in generating an ecosystem where start-up can grow and thrive, with the presence of institutions, academic partners and local and international stakeholders.    Alia Therapeutics has a vision to revolutionize medicine by curing genetic diseases at their roots. Alia’s versatile portfolio of novel CRISPR systems expands the range of targetable genomics sites and increases the precision of genetic modifications, bringing gene editing to the next level of specificity and safety, which is required for therapeutic applications.   #TrentinoSviluppo, #Pergine, #Trentino, #AliaTherapeutics, #CIBIO,#UniversitadiTrento , #geneediting, #CRISPR

Alia Therapeutics is present at ASGCT Baltimore, the 27th Annual Meeting of American Society of Gene & Cell Therapy.  Meet Antonio Casini, Alia co-founder and CTO, on Wednesday 8th, presenting poster on “A novel mutation-independent CRISPR-based gene therapy to treat autosomal dominant retinitis pigmentosa”. POSTER SESSION B6 - Ophthalmic and Auditory Diseases 654   Alia Therapeutics has a vision to revolutionize medicine by curing genetic diseases at their roots. Our thesis: The diversity and complexity of human genetic diseases demands a customized approach and relying on a limited set of enzymes wouldn’t suffice. Alia’s versatile portfolio of novel CRISPR systems expands the range of targetable genomics sites and increases the precision of genetic modifications, bringing gene editing to the next level of specificity and safety, which is required for therapeutic applications. Learn more at https://lnkd.in/dhVhCzw4 #genetherapy, #geneediting, #ASGCT24, #baltimore, #aliatherapeutics

Congratulations to Anna Cereseto and her whole team and collaborators, including our own Antonio Casini and Laura Pezzè, for the recent publication in Nature Communications ‘’CoCas9 is a compact nuclease from the human microbiome for efficient and precise genome editing’’. This work further underscores the strengths and quality of Alia’s discovery platform and versatile portfolio of novel CRISPR systems. Read the full article here: https://lnkd.in/dxwyGusg Alia Therapeutics has a vision to revolutionize medicine by curing genetic diseases at their roots. Our thesis stems from the pioneering work of Anna Cereseto’s lab: the diversity and complexity of human genetic diseases demands a customized approach and relying on a limited set of enzymes wouldn’t suffice. Alia’s versatile portfolio of novel CRISPR systems expands the range of targetable genomics sites and increases the precision of genetic modifications, bringing gene editing to the next level of specificity and safety, which is required for therapeutic applications.   Eleonora Pedrazzoli Matteo Ciciani Michele Demozzi Elisabetta Visentin Ilaria Bonuzzi Laura Pezzè Lorenzo Lucchetta Giulia Maule Annarita Miccio Simone Amistadi Federica Esposito Alberto Auricchio Mariangela Lupo Antonio Casini Nicola Segata Anna Cereseto

Alia Therapeutics is present at #CRISPRMED24, live next week in Copenhagen, the first in person event from CRISPR Medicine News. Meet Alia:  - Antonio Carusillo, Ph.D. will present a poster on Tuesday 23rd at 18:00, Poster #91 " Highly efficient gene editing in human primary T cells using novel CRISPR effectors from the human microbiome"; - Antonio Carusillo, Ph.D. and Antonio Casini will facilitate the educational Workshop ''Choosing the right gene editing approach'' on Wednesday 24th at 8:00; - Antonio Casini on Thursday 25th at 10:30 will present the talk ''A novel portfolio approach to CRISPR-based gene therapies with tailored advantages for human therapeutics''   Alia Therapeutics has a vision to revolutionize medicine by curing genetic diseases at their roots. Our thesis stems from pioneering work of Anna Cereseto’s lab: the diversity and complexity of human genetic diseases demands a customized approach and relying on a limited set of enzymes wouldn’t suffice. Alia’s versatile portfolio of novel CRISPR systems expands the range of targetable genomics sites and increases the precision of genetic modifications, bringing gene editing to the next level of specificity and safety, which is required for therapeutic applications.